Drug Type Small molecule drug |
Synonyms APG 157, APG157 |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication- |
Originator Organization Aveta Biomics, Inc.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Phase 2 | US | Aveta Biomics, Inc.Startup | 13 Dec 2023 |
Recurrent Malignant Glioma | Phase 2 | US | Aveta Biomics, Inc.Startup | 13 Dec 2023 |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | US | Aveta Biomics, Inc.Startup | 22 Apr 2022 |
Squamous cell carcinoma of the oral cavity | Phase 2 | US | Aveta Biomics, Inc.Startup | 22 Apr 2022 |
Squamous Cell Carcinoma of the Oropharynx | Phase 2 | US | Aveta Biomics, Inc.Startup | 22 Apr 2022 |
Squamous Cell Carcinoma | Phase 1 | - | - | |
Squamous Cell Carcinoma | Phase 1 | - | Aveta Biomics, Inc.Startup | - |